Influence of Interferon-α on Cytokine Expression by the Bone Marrow Microenvironment—Impact on Treatment of Myeloproliferative Disorders

Leukemia and Lymphoma

Volumn 22, Issue sup1, 1996, Pages 129-134

  Peschel, C ^a   Aulitzky, W E ^a   Huber, C ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

bone marrow microenvironment; cytokine expression; Interferon alpha; myeloproliferative disorders; treatment

Indexed keywords

ALPHA INTERFERON; CYTOKINE; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 11; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA;

ARTICLE; BONE MARROW; CELL ADHESION; CHRONIC MYELOID LEUKEMIA; CYTOKINE PRODUCTION; DRUG MECHANISM; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL; HUMAN; IMMUNOTHERAPY; MYELOPROLIFERATIVE DISORDER; POLYCYTHEMIA VERA; PRIORITY JOURNAL; PROTEIN SYNTHESIS REGULATION; STROMA CELL; THROMBOCYTHEMIA;

ADIPOSE TISSUE; BIOLOGICAL RESPONSE MODIFIERS; BONE MARROW; CELL ADHESION; CELL DIVISION; CONNECTIVE TISSUE; CYTOKINES; GENE EXPRESSION REGULATION; HEMATOPOIETIC STEM CELLS; HUMANS; INTERFERON-ALPHA; MYELOPROLIFERATIVE DISORDERS;

EID: 0029966249     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428199609074370     Document Type: Article

References (77)

1. Rowley J. D. A new consistent chromosomal abnormality in chronic myelogenous leukemia identified by quinacrine fluorescence and Giemsa staining. Nature 1973; 243: 290
2. Ben-Neriah Y., Daley G. Q., Mes-Masson A. M., Witte O. N., Baltimore D. The chronic myelogenous leukemia-specific p210 protein is the product of the bcr-abl hybrid gene. Science 1986; 233: 212
3. de Klein A., van Kessel A. G., Grosfeld G., Bartram C. R., Hagemeijer A., Bootsma D., Spurr N. K., Heisterkamp N., Groffen J., Stephenson J. R. A cellular oncogene (c-abl) is translocated to the Philadelphia chromosome in chronic myelocytic leukemia. Nature 1982; 294: 765
4. Konopka J. B., Watanabe S. M., Witte O. N. An alteration of the human c-abl protein in K562 cells unmasks associated tyrosine kinase activity. Cell 1984; 37: 1035
5. McWhirter J. R., Wang J. Y. An actin-binding function contributes to transformation by the Bcr-Abl oncoprotein of philadelphia chromosome-positive human leukemias. EMBO J. 1991; 12: 1533
6. Sirard C., Laneuville P., Dick J. E. Expression of bcr-abl abrogates factor-dependent growth of human hematopoietic M07E cells by an autocrine mechanism. Blood 1994; 83: 1575
7. Daley G. Q., Baltimore D. Tranformation of an interleukin 3-dependent hematopoietic cell line by the chronic myelogenous leukemia-specific p210 bcr/abl protein. Proc. Natl. Acad. Sci. U.S.A. 1988; 85: 9312
8. Elefanty A. G., Hariharan I. K., Cory S. bcr-abl, the hallmark of chronic myeloid leukaemia in man, induces multiple haemopoietic neoplasms in mice. EMBO J. 1990; 9: 1069
9. Kelliher M. A., McLaughlin J., Witte O. N., Rosenberg N. Induction of a chronic myelogenous leukemia-like syndrome in mice with v-abl and BCR/ABL. Proc. Natl. Acad. Sci. U.S.A. 1990; 87: 6649
10. Heisterkamp N., Jenster G., ten Hoeve J., Zovich D., Pattengale P. K., Groffen J. Acute leukaemia in bcr/abl transgenic mice. Nature 1990; 344: 251
11. Goldman J. M., Th'ng K. H., Lowenthal R. M. In vitro colony forming cells and colony stimulating factor in chronic granulocytic leukemia. Br. J. Cancer 1974; 30: 1
12. Lepine J., Messner H. A. Pluripotent hemopoietic progenitors (CFU-GEMM) in chronic myelogenous leukemia. Int. J. Cell Cloning 1983; 1: 230
13. Emanuel P. D., Bates L. J., Castleberry R. P., Gualtieri R. J., Zuckerman K. S. Selective hypersensitivity to granulocyte-macrophage colony-stimulating factor by juvenile chronic myeloid leukemia hematopoietic progenitors. Blood 1991; 77: 925
14. Bedi A., Zehnbauer B. A., Barber J. P., Sharkis S. J., Jones R. J. Inhibition of apoptosis by BCR-ABL in chronic myeloid leukemia. Blood 1994; 83: 2038
15. McGahon A., Bissonnette R., Schmitt M., Cotter K. M., Green D. R., Cotter T. G. BCR-ABL maintains resistance of chronic myelogenous leukemia cells to apoptotic cell death. Blood 1994; 83: 1179
16. Bedi A., Barber J. P., Bedi G. C., El-Deiry W. S., Sidransky D., Vala M. S., Akhtar A. J., Hilton J., Jones R. J. BCR-ABL-mediated inhibition of apoptosis with delay of G2/M transition after DNA damage: A mechanism of resistance to multiple anticancer agents. Blood 1995; 86: 1148
17. Schwab R., Peschel C., Derigs G., Fischer T., Huber C., Aulitzky W. E. Deficient cell cycle control upon gamma irradiation and growth factor starvation in immature myeloid cells from chronic phase CML patients Cytokines and Molecular Therapy. 1995
18. Eaves A. C., Cashman J. D., Gaboury L. A., Kalousek D. K., Eaves C. J. Unregulated proliferation of primitive chronic myeloid leukemia progenitors in the presence of normal marrow adherent cells. Proc. Natl. Acad. Sci. U. S. A. 1986; 83: 5306
19. Cashman J. D., Eaves A. C., Eaves C. J. The tetrapeptide AcSDKP specifically blocks the cycling of primitive normal but not leukemic progenitors in long-term culture: evidence for an indirect mechanism. Blood 1994; 84: 1534
20. Gordon M. Y., Dowding C. R., Riley G. P., Goldman J. M., Greaves M. F. Altered adhesive interactions with marrow stroma of haematopoietic progenitor cells in chronic myeloid leukemia. Nature 1987; 328: 342
21. Gordon M. Y., Atkinson J., Clarke D., Dowding C. R., Goldman J. M., Grimsley P. G., Siczkowski M., Greaves M. F. Deficiency of a phosphatidylinositol-anchored cell adhesion molecule influences haemopoietic progenitor binding to marrow stroma in chronic myeloid leukaemia. Leukemia 1991; 5: 693
22. Verfaille C. M., McCarthy J. B., McGlave P. B. Mechanisms underlying abnormal trafficking of malignant progenitors in chronic myelogenous leukemia. Decreased adhesion to stroma and fibronectin but increased adhesion to the basement membrane components laminin and collagen type IV. J. Clin. Invest. 1992; 90: 1992
23. Eaves C. J., Cashman J. D., Wolpe S. D., Eaves A. C. Unresponsiveness of primitive chronic myeloid leukemia cells to macrophage inflammatory protein I alpha, an inhibitor of primitive normal hematopoietic cells. Proc. Natl. Acad. Sci. U. S. A. 1993; 90: 12015
24. Estrov Z., Kurzrock R., Wetzler M., Kantarjian H., Blake Harris M., Gutterman J. U., Talpaz M. Suppression of chronic myelogenous leukemia colony growth by interleukin-1 (IL-1) receptor antagonist and soluble IL-1 receptors: A novel application for inhibitors of IL-1 activity. Blood 1991; 78: 1476
25. Wetzler M., Kurzrock R., Lowe D. G., Kantarjian H., Gutterman J. U., Talpaz M. Alteration in bone marrow adherent layer growth factor expression: No novel mechanism of chronic myelogenous leukemia progression. Blood 1991; 78: 2400
26. Klein H., Becher R., Lübbert M., Oster W., Schleiermacher E., Brach M. A., Souza L., Lindemann A., Mertelsmann R., Herrmann F. Synthesis of granulocyte colony-stimulating factor and its requirement for terminal divisions in chronic myelogenous leukemia progression. J. Exp. Med. 1990; 171: 1785
27. Herrmann F., Helfrich S. G., Lindemann A., Schleiermacher E., Huber C., Mertelsmann R. Elevated circulating levels of tumor necrosis factor predict unresponsiveness to treatment with interferon alpha-2b in chronic myelogenous leukemia. J. Clin. Oncol. 1992; 10: 631
28. Casadevall B., Vainchenker W., Lacombe C. Erythroid progenitors in polycythemia vera: Demonstration of their hypersensitivity to erythropoietin using serum free cultures. Blood 1982; 59: 447
29. Zanjani E. D., Lutton J. D., Hoffman R., Wasserman L. R. Erythroid colony formation by polycythemia vera bone marrow in vitro: Dependence on erythropoietin. J. Clin. Invest. 1977; 59: 841
30. Fisher M. J., Prchal J. F., Prchal J. T., D'Andrea A. D. Anti-erythropoietin (EPO) receptor monoclonal antibodies distinguish EPO-dependent and EPO-independent erythroid progenitors in polycythemia vera. Blood 1994; 84: 1982
31. de Wolf J. T., Hendriks D. W., Esselink M. T., Halie M. R., Vellenga E. The effects of IL-1 and IL-4 on the Epo-independent erythroid progenitor in polycythemia vera. Br. J. Haematol. 1994; 88: 12
32. Dai C. H., Krantz S. B., Dessypris E. N., Means R. T., Horn S. T., Gilbert H. S. Polycythemia vera II. Hypersensitivity of bone marrow erythroid, granulocyte-macrophage and megakaryocyte progenitor cells to interleukin-3 and granulocyte-macrophage colony stimulating factor. Blood 1992; 80: 891
33. de Wolf J. T., Beentjes J. A., Esselink M. T. In polycythemia vera human interleukin 3 and granulocyte-macrophage colony-stimulating factor enhance erythroid colony growth in the absence of erythropoietin. Exp. Hematol. 1989; 17: 981
34. Dai C. H., Krantz S. B., Green W. F., Gilbert H. S. Polycythemia vera III. Burst forming units erythroid (BFU-E) response to stem cell factor and c-kit receptor expression. Br. J. Haematol. 1994; 86: 12
35. Muller E. W., de Wolf J. T., Hendriks D. W., Esselink M. T., Halie M. R., Vellenga E. Recombinant human mast cell growth factor supports erythroid colony formation in polycythemia vera in the presence and absence of erythropoietin and serum. Exp. Hematol. 1995; 21: 1353
36. Correa P. N., Eskinazi D., Axelrad A. A. Circulating erythroid progenitors in polycythemia vera are hypersensitive to insulin-like growth factor-1 in vitro: Studies in an improved serum-free medium. Blood 1994; 83: 99
37. Mirza A. M., Correa P. N., Axelrad A. A. Increased basal and induced tyrosine phosphorylation of the insulin-like growth factor-1 receptor β subunit in circulating mononuclear cells of patients with polycythemia vera. Blood, 86: 877
38. Hehlmann R., Heimpel H. Current aspects of drug therapy in Philadelphia-positive CML: Correlation of tumor burden with survival. Leuk. Lymphoma. 1995
39. Reilly J. T., Vellenga E., de Wolff J. T. M. Interferon treatment in polycythemia vera. Leuk. Lymphoma. 1995
40. Lengfelder E., Griesshammer M., Hehlmann R. Interferon-alpha in the treatment of essential thrombocythemia. Leuk. Lymphoma. 1995
41. Kantarjian H. M., Deisseroth A., Kurzrock R., Estrov Z., Talpaz M. Chronic myelogenous leukemia: A concise update. Blood 1993; 82: 691
42. Aulitzky W. E., Peschel C., Schneller F., Huber C. Biotherapy of chronic myelogenous leukemia. Ann. Hematol., 70: 113
43. Allan N. C., Shepherd P. C. A., Richards S. M. UK Medical Research Council randomised multicentre trial of interferon alpha n1 for chronic myeloid leukemia: Improved survival irrespective of cytogenetic response. Lancet 1995; 345: 1392
44. The Italian Cooperative Study Group on Chronic Myeloid Leukaemia. Interferon alpha-2a as compared with conventional chemotherapy for the treatment od chronic myeloid leukemia. N. Engl. J. Med. 1994; 330: 820
45. Messora C., Bensi L., Vecchi A., Longo R., Giacobbi F., Temperani P., Bevini M., Emilia G., Sacchi S. Cytogenetic conversion in a case of polycythaemia vera treated with interferon-alpha. Brit. J. Haematol. 1994; 86: 402
46. Broxmeyer H. E., Lu L., Platzer E., Felt C., Juliano L., Rubin B. Y. Comparative analysis of the influences of human gamma, alpha and beta interferons on human multipotential (CFU-GEMM), erythroid (BFU-e) and granulocyte-macrophage (CFU-GM) progenitor cells. J. Immunol. 1983; 131: 1300
47. Raefsky E. L., Platanias L. C., Zoumbos N. C., Young N. S. Studies of interferon as a regulator of hematopoietic cell proliferation. J. Immunol. 1985; 135: 2507
48. Ganser A., Carlo-Stella C., Greher J., Völkers B., Hoelzer D. Effect of recombinant interferons alpha and gamma on human bone marrow-derived megakaryocytic progenitor cells. Blood 1987; 70: 1173
49. Geissler D., Gastl G., Aulitzky W. E., Tilg H., Gaggl S., Kon-Walinka G., Huber C. Recombinant interferon alpha-2c in chronic myelogenous leukemia: relationship of sensitivity of committed haematopoietic precursor cells in vitro. Leuk. Res. 1990; 14: 629
50. Dowding C., Guo A. P., Maisin D., Gordon M. Y., Goldman J. M. The effects of interferon-alpha on the proliferation of CML progenitor cells in vitro are not related to the precise position of the M-BCR breakpoint. Brit. J. Haematol. 1991; 77: 165
51. Mazur E. M., Richtsmeier W. J., South K. Alpha-interferon: differential suppression of colony growth from human erythroid, myeloid, and megakaryocytic hemopoietic progenitor cells. J. Interferon. Res. 1986; 6: 199
52. Galvani D. W., Cawley J. C. Mechanism of action of alpha interferon in chronic granulocytic leukaemia: evidence for preferential inhibition of late progenitors. Brit. J. Haematol. 1989; 73: 475
53. Després D, Goldschmitt J, Aulitzky W. E., Huber C., Peschel C. Differential effect of type 1 interferons on hematopoietic progenitor cells: Failure of IFNs to inhibit immature myeloid progenitor cells from normal bone marrow and chronic myelogeneous leukemia. [In Press. Exp. Hematol. 1995
54. Lotem J., Sachs L. Selective regulation of the activity of different hematopoietic regulatory proteins by transforming growth factor beta 1 in normal and leukemic myeloid cells. Blood 1990; 76: 1315
55. Moore S. C., Theus S. A., Barnett J. B., Soderberg L. S. Bone marrow natural suppressor cells inhibits the growth of myeloid progenitor cells and the synthesis of colony-stimulating factors. Exp. Hematol. 1992; 20: 1178
56. Keller J. R., Bartelmez S. H., Sitnicka E., Ruscetti F. W., Ortiz M., Gooya J. M., Jacobsen S. E. Distinct and overlapping direct effects of macrophage inflammatory protein-1 alpha and transforming growth factor beta on hematopoietic progenitor/stem cell growth. Blood 1994; 84: 2175
57. Dowding C., Guo A. P., Osterholz J., Siczkowski M., Goldman J. M., Gordon M. Y. Interferon-alpha overrides the deficient adhesion of chronic myeloid primitive progenitor cells to bone marrow stromal cells. Blood 1991; 78: 499
58. Upadhyaya G., Cuba S. C., Sih S. A., Feinberg A. P., Talpaz M., Kantarjian H. M., Deisseroth A. B., Emerson S. G. Interferon-alpha restores the deficient expression of the cytoadhesion molecule lymphocyte function antigen-3 by chronic myelogenous leukemia progenitor cells. J. Clin. Invest. 1991; 88: 2131
59. Bhatia R., Wayner E. A., McGlave P. B., Verfaillie C. M. Interferon-alpha restores normal adhesion of chronic myelogenous leukemia hematopoietic progenitors to bone marrow stroma by correcting impaired beta 1 integrin receptor function [see comments]. J. Clin. Invest. 1994; 94: 384
60. Santucci M. A., Soligo D., Piled S., Zuffa E., Testoni N., Tura S. Interferon-alpha effects on stromal compartment of normal and chronic myeloid leukemia hematopoiesis. Leuk. Lymphoma, 11 (Suppl 1) 113
61. Beelen D. W., Graeven U., Elmaagacli A. H., Niederle N., Kloke O., Opalka B., Schaefer U. W. Prolonged administration of interferon-alpha in patients with chronic-phase Philadelphia chromosome-positive chronic myelogenous leukemia before allogeneic bone marrow transplantation may adversely affect transplant outcome. Blood 1995; 85: 2981
62. Aman M. J., Keller U., Derigs G., Mohamadzadeh M., Huber C., Peschel C. Regulation of cytokine expression by interferon alpha in human bone marrow stromal cells: Inhibition of hematopoietic growth factors and induction of IL-1 receptor antagonist. Blood 1994; 83: 4142
63. Aman M. J., Rudolf G., Goldschmitt J., Aulitzky W. E., Lam C., Huber C., Peschel C. Type I interferons are potent inhibitors of interleukin-8 production in hematopoietic and bone marrow stromal cells. Blood 1993; 82: 2371
64. Aman M. J., Bug G., Huber C., Peschel C. Inhibition of interleukin-11 by interferon-alpha in human bone marrow stromal cells. 1995
65. Schindler R., Ghezzi P., Dinarello C. A. IL-1 induces IL-1. IV. IFN-gamma suppresses IL-1 but not lipopolysaccaride-induced transcription of IL-1. J. Immunol. 1990; 144: 2216
66. Bartelmez S. H., Stanley R. E. Synergism between hemopoietic growth factors (HGFs) detected by their effects on cells bearing receptors for a lineag specific HGF: Assay for hemopoietin-1. J. Cell. Physiol. 1985; 122: 370
67. Mochizuki D. Y., Eisenman J. F., Conlon P. J., Larsen A. D., Tushinski R. J. Interleukin 1 regulates hematopoietic activity, a role previously ascribed to hemopoietin 1. Proc. Natl. Acad. Sci. U. S. A. 1987; 84: 5267
68. Yang Y.-C., Tsai S., Wong G. G., Clark S. C. Interleukin-1 regulation of hematopoietic growth factor production by human stromal fibroblasts. J. Cell. Physiol. 1988; 134: 292
69. Fibbe W. E., Gosenlink H. M., Van Eeden G., Van Damme J., Biliau A., Voogt P. J., Willemze R., Falkenburg J. H. F. Proliferation of myelopid progenitor cells in human longterm bone marrow cultures is stimulated by interleukin-1 beta. Blood 1988; 72: 1242
70. Van Damme J., Opdenakker G., Simpson R. J., Rubira M. R., Cayphas S., Vink A., Biliau A., Van Snick J. Identification of the human 26 kD protein, interferon β2 (IFN-β2), as a B cell hybridoma/plasmacytoma growth factor induced by interleukin 1 and tumor necrosi. factor. J. Exp. Med. 1987; 165: 914
71. Elias J. A., Zheng T., Whiting N. L., Trow T. K., Merrill W. W., Zitnik R., Ray P., Alderman E. M. IL-1 and transforming growth factor-beta regulation of fibroblast-derived IL-11. J. Immunol. 1994; 152: 2421
72. Yang L., Yang Y. C. Regulation of interleukin (IL)-11 gene expression in IL-1 induced primate bone marrow stromal cells. J. Biol. Chem. 1994; 269: 32732
73. Aye M. T., Hashemi S., Leclair B., Zeibdawi A., Trudel E., Halpenny M., Fuller V., Cheng G. Expression of stem cell factor and c-kit mRNA in cultured endothelial cells, monocytes and cloned human bone marrow cells (CFU-RF). Exp. Hematol. 1992; 20: 523
74. Koenig A., Yakisan E., Reuter M., Huang M., Sykora K. W., Corbacioglu S., Welte K. Differential regulation of stem cell factor mRNA expression in human endothelial cells by bacterial pathogens: an in vitro model of inflammation. Blood 1994; 83: 2836
75. Tilg H., Mier J. W., Vogel W., Aulitzky W. E., Wiedemann C. J., Vannier E., Huber C., Dinarello C. A. Induction of circulating IL-1 receptor antagonist by IFN treatment. J. Immunol. 1993; 150: 4687
76. Peschel C., Bug G., Aman M. J., Huber C. Tissue specific regulation of the expression of macrophage inflammatory protein 1α (MIP-1α). [Abstract. Exp. Hematol. 1995; 23: 93
77. Wadenvik H., Kutti J., Ridell B., Revesz P., Jacobsson S., Magnusson B., Westin J., Vilen L. The effect of α-interferon on bone marrow megakaryocytes and platelet production rate in essential thrombocythemia. Blood 1991; 77: 2103